palmitoylethanolamide.com.au
HomeResearchTahereh 2021

Burning mouth syndrome: a review of therapeutic approach

Tahereh Nosratzehi. J Complement Integr Med. 2021 Dec 9;19(1):83-90.

ReviewHumans

Design
Review
Subjects
Not stated in the abstract
Dose used in the study
Not stated in the abstract
Duration
Not stated in the abstract
What was measured
What treats burning mouth syndrome: a survey of pharmacological options, including ultramicronised palmitoylethanolamide, and non-pharmacological approaches, drawn from PubMed/MEDLINE, Cochrane Library and Web of Science

What the authors reported

The author lists pharmacological treatments used for burning mouth syndrome, including capsaicin, clonazepam, low-dose aripiprazole, alpha-lipoic acid, duloxetine, amitriptyline, gabapentin, pregabalin and ultramicronised palmitoylethanolamide, plus non-pharmacological options such as cognitive therapy, laser therapy, acupuncture and rTMS. No treatment is confirmed as a standard.

Limits of this study

A narrative review with no trial numbers or effect sizes given for palmitoylethanolamide. Funding and conflicts not stated in the abstract.

Source

PubMed 34881535 · doi:10.1515/jcim-2021-0434

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.